Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and Hepatitis C
This study has been completed.
Sponsor:
French National Agency for Research on AIDS and Viral Hepatitis
Collaborator:
Hoffmann-La Roche
Information provided by (Responsible Party):
French National Agency for Research on AIDS and Viral Hepatitis
ClinicalTrials.gov Identifier:
NCT00122616
First received: July 19, 2005
Last updated: February 21, 2012
Last verified: February 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The aim of this study is to prove the efficacy of peginterferon in HIV infected patients with liver disease caused by hepatitis C virus (HCV) when the treatment to eradicate the virus failed. This scientific proof needs a comparative study to be done including two groups of patients randomly allocated: one with the treatment (peginterferon) and the other without any treatment against HCV with a duration of 2 years. To conclude, two liver biopsies are needed; one before the study and a second 2 years after.
| Condition | Intervention | Phase |
|---|---|---|
|
HIV Infections Hepatitis C, Chronic |
Biological: Peginterferon alpha-2a (Pegasys®) Drug: Ribavirin Drug: HIV antiretroviral therapy |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and C Hepatitis Who Failed to Active Treatment for HCV. ANRSHC12 Fibrostop |
Resource links provided by NLM:
Genetics Home Reference related topics:
North American Indian childhood cirrhosis
U.S. FDA Resources
Further study details as provided by French National Agency for Research on AIDS and Viral Hepatitis:
Primary Outcome Measures:
- Percentage of patients who experienced one point decreases of their fibrosis histological score (Metavir). [ Time Frame: Week 96 ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Distribution of the change of fibrosis Metavir score in each group [ Time Frame: Week 96 ] [ Designated as safety issue: No ]
- Distribution of fibrosis score from Chevallier classification [ Time Frame: Week 96 ] [ Designated as safety issue: No ]
- Plasmatic fibrosis markers dosages [ Time Frame: Week 96 ] [ Designated as safety issue: No ]
- Viral load quantification for HIV and HCV [ Time Frame: Week 96 ] [ Designated as safety issue: No ]
- Number and percentage of CD4/CD8 cell count throughout the study [ Time Frame: Day 0 to week 96 ] [ Designated as safety issue: No ]
- Number and percentage of patient had more thand 200 copies/ml throughout the study [ Time Frame: Day 0 to week 96 ] [ Designated as safety issue: No ]
- Occurrence of hepatic complication related to HCV [ Time Frame: Day0 to week 96 ] [ Designated as safety issue: No ]
- Survival throughout the study [ Time Frame: Day 0 to week 96 ] [ Designated as safety issue: No ]
- Quality of life questionnaire [ Time Frame: Day 0 to week 96 ] [ Designated as safety issue: No ]
- Fibrotest (plasmatic fibrosis marker) [ Time Frame: Day 0, week 48 and week 96 ] [ Designated as safety issue: No ]
- Histological improvement according to the total interferon dose received [ Time Frame: Day 0 to week 96 ] [ Designated as safety issue: No ]
| Enrollment: | 52 |
| Study Start Date: | November 2003 |
| Study Completion Date: | March 2009 |
| Primary Completion Date: | March 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Peginterféron alpha-2a + Ribavirin+ HIV antiretroviral therapy
Day0 to week 96:Peginterféron alpha-2a + Ribavirin+ HIV antiretroviral therapy
|
Biological: Peginterferon alpha-2a (Pegasys®)
Peg-Interferon Alpha2a by subcutaneous injection, 180µg, once weekly
Drug: Ribavirin
Ribavirin: tablet oral, weight-based dose, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over 75 kg, once daily
Drug: HIV antiretroviral therapy
All antiretroviral drugs are allowed, their choice being left to the discretion of the investigator. Particular attention will be carried to the patients with antiretroviral susceptible to cause a cumulative toxicity with anti-VHC drugs
|
|
Placebo Comparator: HIV antiretroviral therapy
Day0 to week 96: HIV antiretroviral therapy
|
Drug: HIV antiretroviral therapy
All antiretroviral drugs are allowed, their choice being left to the discretion of the investigator. Particular attention will be carried to the patients with antiretroviral susceptible to cause a cumulative toxicity with anti-VHC drugs
|
Detailed Description:
C hepatitis in HIV infected patient becomes a major issue although the survival of patients, has improved in the last decades regarding to the advent of HAART, the mortality related to liver disease has increased in this population. Sustained virological response for HCV can be obtained with peg-interferon and ribavirin treatment but more or less 50% of patients experienced failure to this treatment and liver fibrosis due to HCV infection progress and may lead to cirrhosis and hepato-carcinoma. To demonstrate the efficacy of peginterferon therapy to reduce the liver damage causes by HCV infection, a randomised controlled study is needed comparing one group of patient treated by peginterferon and one group without any treatment against HCV infection. In order to show 30% difference between the two groups in reducing one point of fibrosis score (METAVIR scale), 150 patients are needed. The duration of the study is 96 weeks
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- HIV infection (Western Blot +)
- C hepatitis (RNA viral hepatitis C [VHC] +)
- Chronic active C hepatitis on liver histological score METAVIR (A over or equal to 1 and F over or equal to 2) on biopsy performed at least 18 months before the expected date of inclusion
- Previous treatment for C hepatitis for at least 3 months including peg-interferon and ribavirin or peg-interferon alone if counterindication for ribavirin occurred
- Failure to eradicate C hepatitis virus after well conducted treatment
- The liver biopsy should have been realised at least 18 months before inclusion :
Either before treatment for C hepatitis in patients treated at most 7 months Or at least 6 months after anti HCV treatment in patient treated for more than 7 months (wash out period)
- Regular follow up in an outpatient clinic for HIV
- Unchanged antiretroviral treatment the last 3 months before inclusion
- Inform consent
Exclusion Criteria:
- History of transplantation or clinical hepatic failure
- Opportunistic infection in the past three months before inclusion
- Any hepatic disease not related to HCV (B hepatitis, hemochromatosis, Wilson disease)
- Diabetes mellitus
- Immunocompromised treatment
- Active intravenous drug addiction
- Alcohol consumption of more than 50 g per day
- Counterindication for the use of interferon
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00122616
Please refer to this study by its ClinicalTrials.gov identifier: NCT00122616
Locations
| France | |
| Service de Maladies Infectieuses et de Réanimation Médicale | |
| Rennes, France, 35033 | |
Sponsors and Collaborators
French National Agency for Research on AIDS and Viral Hepatitis
Hoffmann-La Roche
Investigators
| Principal Investigator: | Jean Marc Chapplain, MD | Hopital Pontchaillou Rennes |
| Study Chair: | Eric Belissant, MD | CIC Hôpital Pontchaillou Rennes |
More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | French National Agency for Research on AIDS and Viral Hepatitis |
| ClinicalTrials.gov Identifier: | NCT00122616 History of Changes |
| Other Study ID Numbers: | ANRSHC12 FIBROSTOP |
| Study First Received: | July 19, 2005 |
| Last Updated: | February 21, 2012 |
| Health Authority: | France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) |
Keywords provided by French National Agency for Research on AIDS and Viral Hepatitis:
|
HIV infections peginterferon alfa-2a Treatment Failure Hepatitis C, Chronic Treatment Experienced |
Additional relevant MeSH terms:
|
Hepatitis Hepatitis A Hepatitis C HIV Infections Fibrosis Hepatitis C, Chronic Liver Cirrhosis Liver Diseases Digestive System Diseases Hepatitis, Viral, Human Virus Diseases Enterovirus Infections Picornaviridae Infections RNA Virus Infections Flaviviridae Infections |
Lentivirus Infections Retroviridae Infections Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Pathologic Processes Hepatitis, Chronic Interferons Ribavirin Peginterferon alfa-2a Interferon-alpha Antineoplastic Agents Antiviral Agents Anti-Infective Agents |
ClinicalTrials.gov processed this record on September 27, 2016